Back to top
more

Aldeyra Therapeutics (ALDX)

(Delayed Data from NSDQ)

$3.93 USD

3.93
267,876

-0.01 (-0.25%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.92 -0.01 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ALDX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Aldeyra Therapeutics, Inc. [ALDX]

Reports for Purchase

Showing records 21 - 40 ( 41 total )

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 21

12/21/2021

Company Report

Pages: 4

TRANQUILITY Results Not Tranquil; Remain Hopeful in TRANQUILITY-2 Data in Mid-2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: ZHANG E

Price: 5.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 22

11/02/2021

Daily Note

Pages: 4

Phase 2 Trial in Dry Eye Disease Shows Positive Results on Ocular Redness

Provider: H.C. Wainwright & Co., Inc.

Analyst: ZHANG E

Price: 5.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 23

10/29/2021

Company Report

Pages: 5

Ph3 TRANQUILITY Trial Data Coming Soon; Potential NDA Filing in Dry Eye Disease Expected in Early 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: ZHANG E

Price: 5.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 24

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ALDX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 25

08/05/2021

Company Report

Pages: 5

Reproxalap TRANQUILITY Trials Remain On Track; ADX-2191 Bringing New Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: ZHANG E

Price: 10.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 26

05/06/2021

Company Report

Pages: 5

A Solid First Quarter and More Catalysts Expected to Come Later This Year; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ZHANG E

Price: 10.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 27

05/03/2021

Company Report

Pages: 6

Positive Phase 3 INVIGORATE Results Bode Well for Reproxalap in Ocular Diseases; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ZHANG E

Price: 25.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 28

03/12/2021

Company Report

Pages: 5

INVIGORATE AC Top-line Data Upcoming; 4Q20 Recap

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 29

02/08/2021

Company Report

Pages: 38

The Catcher in the Eye; Initiating Coverage With a Buy and $26 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 30

10/06/2017

Company Report

Pages: 3

We are terminating coverage due to the departure from the firm of the covering analyst

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 31

08/09/2017

Company Report

Pages: 7

Q2 Results; Begone Stink Eye if Dry Eye P2 in Sept. Works

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 25.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 32

06/15/2017

Daily Note

Pages: 4

Slight Miss on Component of Primary Seems Like an Itch Aldeyra can Scratch

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 33

03/31/2017

Company Report

Pages: 6

Aldeyra Queues Up Another Data-Filled Year With New Dry Eye Candidate

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 25.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 34

11/15/2016

Company Report

Pages: 4

Q3 Reinforces That 2017 Will Be the Pivotal Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 35

09/27/2016

Daily Note

Pages: 4

Extinguishing Inflammation With New Programs; Especially Dry Eye

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 36

09/26/2016

Company Report

Pages: 23

Trapping Season Opens Early-Biggest Drug Target You''ve Never Heard of; Initiating with $18 Target

Provider: H.C. Wainwright & Co., Inc.

Price: 75.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 37

08/13/2015

Company Report

Pages: 5

Maneuvering Through a Clinical Development Hiccup; New $13 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 38

05/14/2015

Company Report

Pages: 5

On Track to Report Clinical Data in 2H15; Reiterate Buy

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 39

03/20/2015

Company Report

Pages: 5

With Clinical Trials Underway, Focus Turns to Data; Raising Price Target

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Aldeyra Therapeutics, Inc.

Industry: Medical - Drugs

Record: 40

01/12/2015

Daily Note

Pages: 25

2015 Preview: Industry Signals Imply Continued Growth

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: RAMAKANTH S

Price: 75.00

Research Provided by a Third Party